Focused On-demand Library for Phosphatidylinositol-glycan biosynthesis class F protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q07326

UPID:

PIGF_HUMAN

Alternative names:

GPI11 homolog

Alternative UPACC:

Q07326; Q8WW20

Background:

The Phosphatidylinositol-glycan biosynthesis class F protein, also known as GPI11 homolog, plays a crucial role in GPI-anchor biosynthesis. This process is essential for attaching various proteins to cell membranes, influencing cell surface structure and signaling. The protein's action involves the transfer of ethanolamine phosphate to the third mannose of GPI, a key step in the biosynthesis pathway.

Therapeutic significance:

Linked to the rare Onychodystrophy, osteodystrophy, impaired intellectual development, and seizures syndrome, the GPI11 homolog's dysfunction underscores its biological importance. Understanding the role of Phosphatidylinositol-glycan biosynthesis class F protein could open doors to potential therapeutic strategies for this autosomal recessive disorder.